Evidence map›Paper›PMID 36071758›Full record

ReviewJournal of thoracic disease2022

Management of perioperative bleeding risk in patients on antithrombotic medications undergoing cardiac surgery-a systematic review.

Marijana Matejic-Spasic, Kambiz Hassan, Matthias Thielmann, Stephan Geidel, Robert F Storey, Michael Schmoeckel, Harriet Adamson, Efthymios N Deliargyris, Daniel Wendt

Open access · diamondAbstract readReview
In one paragraph

Review in Journal of thoracic disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Impact of extracorporeal circuits on systemic drug levels - a scoping review.Journal of anesthesia, analgesia and critical care · 2026
    Review
  4. Article
  5. 2024 EACTS/EACTAIC Guidelines on patient blood management in adult cardiac surgery in collaboration with EBCP.European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery · 2025
    Article
  6. Article
  7. Intraoperative Hemoadsorption in Heart Transplant Surgery: A 5-Year Experience.Journal of cardiovascular development and disease · 2025
    Article
  8. Observational
  9. Article
  10. Review
  11. Safety of Andexanet Alfa Use in Cardiac Surgery.Journal of cardiothoracic and vascular anesthesia · 2023
    Article
  12. Article
  13. Review
  14. StandardizedFrontiers in cardiovascular medicine · 2023
    Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Marijana Matejic-SpasicCytoSorbents Inc., Monmouth Junction, NJ, USA.
Kambiz HassanDepartment of Cardiac Surgery, Asklepios Klinik St. Georg, Hamburg, Germany.
Matthias ThielmannDepartment of Thoracic and Cardiovascular Surgery, Westgerman Heart and Vascular Center, Essen, Germany.
Stephan GeidelDepartment of Cardiac Surgery, Asklepios Klinik St. Georg, Hamburg, Germany.
Robert F StoreyDepartment of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.
Michael SchmoeckelDepartment of Cardiac Surgery, Asklepios Klinik St. Georg, Hamburg, Germany.
Harriet AdamsonCytoSorbents Inc., Monmouth Junction, NJ, USA.
Efthymios N DeliargyrisCytoSorbents Inc., Monmouth Junction, NJ, USA.
Daniel WendtCytoSorbents Inc., Monmouth Junction, NJ, USA.
CytoSorbents (United States) · USAsklepios Klinik St. Georg · DEUniversity of Sheffield · GBWest German Heart and Vascular Center Essen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Antithrombotic drugs increase the risk of bleeding, especially in patients who need urgent surgery without an adequate wash-out period. This review aims to evaluate perioperative bleeding complications in patients on dual antiplatelet therapy (DAPT) or direct-acting oral anticoagulants (DOACs) undergoing high-bleeding risk cardiovascular surgery and to present currently available potential solutions to mitigate antithrombotic therapy-related bleeding complications. Methods: As a first step, we searched for relevant articles, over the last 10 years, in Medline (PubMed) and abstracted clinical information based on pre-defined criteria for bleeding complications. In the next step, an additional search evaluating potential solutions to mitigate bleeding complications was performed. The literature screening and selection process followed the principles derived from the PRISMA statement. Results: From all reviewed studies, a total of 19 articles could be included evaluating the risk for bleeding in cardiac surgery related to DAPT or DOACs and 10 papers evaluating antithrombotic drug reversal or removal in the setting of cardiovascular surgery. Reported bleeding rates ranged between 18% and 41%. The variability of the reported data is remarkable. Idarucizumab is reported to provide optimal perioperative hemostasis in up to 93% of patients. It has been observed that andexanet alfa causes unresponsiveness to the anticoagulant effects of heparin. Antithrombotic removal by intraoperative hemoadsorption is found to be associated with a significant decrease in re-thoracotomy rate, overall procedure duration, administered transfusion volumes, chest-tube drainage, and length of hospitalization. Discussion: Bleeding complications in patients treated with DAPT or DOACs in cardiac surgery are high. New costly reversal agents are available but have not been sufficiently tested in the cardio-surgical setting so far. Interestingly, bleeding-related complications seem to be effectively reduced by applying innovative intraoperative hemoadsorption techniques. Expected results from the ongoing trials should provide better insights concerning the efficacy and safety of several potential solutions. Currently, the variability of reports and the deficit of high-quality studies in this specific setting represent the major limitation for the unbiased conclusion of this review.

Indexed as

anticoagulantsantiplateletsbleedingCardiac surgeryhemoadsorption

Identifiers

PMID36071758
PMCPMC9442533
OpenAlexW4288071438

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.